Pontiroli A E, Perfetti M G, Pozza G
Istituto Scientifico S. Raffaele, Università di Milano, Italy.
Horm Metab Res Suppl. 1992;26:32-4.
Obesity and impaired glucose tolerance (IGT) are risk factors for non insulin dependent diabetes mellitus (NIDDM) and for ischemic heart disease. Long term treatment of IGT subjects with diet and tolbutamide prevents progression of IGT to NIDDM. We have evaluated the lowest dose of glipizide, a second-generation sulfonylurea, able to improve glucose tolerance in response to oral glucose in 31 obese subjects, 12 with NIDDM, 9 with IGT and 10 with normal glucose tolerance (NGT). All subjects underwent four OGTTs, preceded by placebo and by different doses of glipizide (0.5, 1.0, 2.5 mg). Glucose tolerance was progressively improved by increasing glipizide doses in all groups, probably by peripheral mechanism and by enhanced insulin release.
肥胖和糖耐量受损（IGT）是非胰岛素依赖型糖尿病（NIDDM）和缺血性心脏病的危险因素。对IGT受试者进行长期饮食和甲苯磺丁脲治疗可预防IGT进展为NIDDM。我们评估了第二代磺脲类药物格列吡嗪的最低剂量，该剂量能够改善31名肥胖受试者口服葡萄糖后的糖耐量，其中12名患有NIDDM，9名患有IGT，10名糖耐量正常（NGT）。所有受试者均接受了四次口服葡萄糖耐量试验（OGTT），试验前分别服用安慰剂和不同剂量的格列吡嗪（0.5、1.0、2.5毫克）。在所有组中，随着格列吡嗪剂量的增加，糖耐量逐渐改善，这可能是通过外周机制和增强胰岛素释放实现的。
